Evidence map›Paper›PMID 26034631›Full record

ArticleNeuro-oncology practice2014

Primary brain tumors and posterior reversible encephalopathy syndrome.

Carlos Kamiya-Matsuoka, David Cachia, Adriana Olar, Terri S Armstrong, Mark R Gilbert

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Posterior reversible encephalopathy syndrome in glioblastoma.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Neurological and Medical Complications in Brain Tumor Patients.Current neurology and neuroscience reports · 2020
    Review
  8. Neurological complications of systemic tumor therapy.Wiener medizinische Wochenschrift (1946) · 2019
    Review
  9. Article
  10. Article
  11. Article
  12. Posterior reversible encephalopathy syndrome (PRES): a rare condition after resection of posterior fossa tumors: two new cases and review of the literature.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2016
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Carlos Kamiya-MatsuokaDepartment of Neuro-Oncology , The University of Texas MD Anderson Cancer Center , Houston, Texas (C.K.-M., D.C., T.S.A., M.R.G.); Department of Family Health , The University of Texas Health Science Center School of Nursing , Houston, Texas (T.S.A.); Department of Pathology , The University of Texas MD Anderson Cancer Center , Houston, Texas (A.O.).
David CachiaDepartment of Neuro-Oncology , The University of Texas MD Anderson Cancer Center , Houston, Texas (C.K.-M., D.C., T.S.A., M.R.G.); Department of Family Health , The University of Texas Health Science Center School of Nursing , Houston, Texas (T.S.A.); Department of Pathology , The University of Texas MD Anderson Cancer Center , Houston, Texas (A.O.).
Adriana OlarDepartment of Neuro-Oncology , The University of Texas MD Anderson Cancer Center , Houston, Texas (C.K.-M., D.C., T.S.A., M.R.G.); Department of Family Health , The University of Texas Health Science Center School of Nursing , Houston, Texas (T.S.A.); Department of Pathology , The University of Texas MD Anderson Cancer Center , Houston, Texas (A.O.).
Terri S ArmstrongDepartment of Neuro-Oncology , The University of Texas MD Anderson Cancer Center , Houston, Texas (C.K.-M., D.C., T.S.A., M.R.G.); Department of Family Health , The University of Texas Health Science Center School of Nursing , Houston, Texas (T.S.A.); Department of Pathology , The University of Texas MD Anderson Cancer Center , Houston, Texas (A.O.).
Mark R GilbertDepartment of Neuro-Oncology , The University of Texas MD Anderson Cancer Center , Houston, Texas (C.K.-M., D.C., T.S.A., M.R.G.); Department of Family Health , The University of Texas Health Science Center School of Nursing , Houston, Texas (T.S.A.); Department of Pathology , The University of Texas MD Anderson Cancer Center , Houston, Texas (A.O.).
The University of Texas Health Science Center at Houston · USThe University of Texas MD Anderson Cancer Center · US

Funding

Multidisciplinary Subspecialty Pathology Research Fellowship ProgramT32CA163185 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CZERNIAK, BOGDAN A, KEYOMARSI, KHANDAN · 2011 to 2015
$1.7M
NCI NIH HHS T32 CA163185
6 · The paper itself

Abstract

backgroundPosterior reversible encephalopathy syndrome (PRES) is a neurotoxic encephalopathic state associated with reversible cerebral vasogenic edema. It is an increasingly recognized occurrence in the oncology population. However, it is very uncommon in patients with primary brain tumors (PBTs). The aim of this study was to analyze the clinicoradiological features and report the clinical outcomes of PRES in PBT patients.

methodsWe identified 4 cases with PBT who developed PRES at MD Anderson Cancer Center (MDACC) between 2012 and 2014. Clinical and radiological data were abstracted from their records. In addition, we also solicited 8 cases from the literature.

resultsThe median age at PRES onset was 19 years, male-to-female ratio was 1:1, and the syndrome occurred in patients with ependymoma (

conclusionsHypertension seems to be the most important coexisting risk factor for development of PRES; however, the potential effects of chemotherapeutic agents in the pathogenesis of PRES should also be examined. The clinicoradiological course of PRES in PBT patients did not vary from the classical descriptions of PRES found in other causes. PRES must be considered as part of the differential diagnosis in patients with PBTs presenting with seizures or acute encephalopathy.

Indexed as

bevacizumabglioblastomagliomaposterior reversible encephalopathy syndromeprimary brain tumor

Identifiers

PMID26034631
PMCPMC4369712
OpenAlexW2136238758

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.